Long-Term Protective Immunity from an Influenza Virus-Like Particle Vaccine Administered with a Microneedle Patch

Quan, Fu‐Shi; Kim, Yeu Chun; Song, June O.; Hwang, Hye Suk; Compans, Richard W.; Prausnitz, Mark R.; Kang, Sang‐Moo

doi:10.1128/cvi.00251-13

Cited by 58 publications

(30 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While five months is an endpoint of our experiment for determining the long-term immunity of the yeast vaccine, it is predicted that the immunity could still be maintained at a higher level after five months. The virus-like particle (VLP) vaccine has been shown to induce long-term protection of mice from influenza virus infection [50, 51]. However, construction and production of these VLP vaccines at an industry scale are cumbersome [52].…”

Section: Resultsmentioning

confidence: 99%

Yeast Surface-Displayed H5N1 Avian Influenza Vaccines

Han

Jin

Karlsson

et al. 2016

Journal of Immunology Research

View full text Add to dashboard Cite

Highly pathogenic H5N1 avian influenza viruses pose a pandemic threat to human health. A rapid vaccine production against fast outbreak is desired. We report, herein, a paradigm-shift influenza vaccine technology by presenting H5N1 hemagglutinin (HA) to the surface of yeast. We demonstrated, for the first time, that the HA surface-presented yeast can be used as influenza vaccines to elicit both humoral and cell-mediated immunity in mice. The HI titer of antisera reached up to 128 in vaccinated mice. A high level of H5N1 HA-specific IgG1 and IgG2a antibody production was detected after boost immunization. Furthermore, we demonstrated that the yeast surface-displayed HA preserves its antigenic sites. It preferentially binds to both avian- and human-type receptors. In addition, the vaccine exhibited high cross-reactivity to both homologous and heterologous H5N1 viruses. A high level production of anti-HA antibodies was detected in the mice five months after vaccination. Finally, our animal experimental results indicated that the yeast vaccine offered complete protection of mice from lethal H5N1 virus challenge. No severe side effect of yeast vaccines was noted in animal studies. This new technology allows for rapid and large-scale production of influenza vaccines for prepandemic preparation.

show abstract

Section: Resultsmentioning

confidence: 99%

Yeast Surface-Displayed H5N1 Avian Influenza Vaccines

Han

Jin

Karlsson

et al. 2016

Journal of Immunology Research

View full text Add to dashboard Cite

show abstract

“…Many groups have examined the use of MNs for immunization against a range of diseases. For example, superior titers and dose-sparing over traditional injection have been reported for measles [81], rotavirus [82], and various strains of influenza [83]–[85]. For influenza immunization, one study utilized dissolving MNs to deliver inactivated influenza virus (strain A/PR/8/34, H1N1) [85].…”

Section: Areas Of Potential Impactmentioning

confidence: 99%

Skin permeabilization for transdermal drug delivery: recent advances and future prospects

Schoellhammer

Blankschtein

Langer³

2014

Expert Opinion on Drug Delivery

296

188

View full text Add to dashboard Cite

Introduction Transdermal delivery has potential advantages over other routes of administration. It could reduce first-pass metabolism associated with oral delivery and is less painful than injections. However, the outermost layer of the skin, the stratum corneum (SC), limits passive diffusion to small lipophilic molecules. Therefore, methods are needed to safely permeabilize the SC so that ionic and larger molecules may be delivered transdermally. Areas Covered This review focuses on low-frequency sonophoresis, microneedles, electroporation and iontophoresis, and combinations of these methods to permeabilize the SC. The mechanisms of enhancement and developments in the last five years are discussed. Potentially high-impact applications, including protein delivery, vaccination, and sensing, are presented. Finally, commercial interest and clinical trials are discussed. Expert Opinion Not all permeabilization methods are appropriate for all applications. Focused studies into applications utilizing the advantages of each method are needed. The total dose and kinetics of delivery must be considered. Vaccination is one application where permeabilization methods could make an impact. Protein delivery and analyte sensing are also areas of potential impact, although the amount of material that can be delivered (or extracted) is of critical importance. Additional work on the miniaturization of these technologies will help to increase commercial interest.

show abstract

“…The HAI titers in the serum were determined as previously described [Quan et al, 2013]. Sera from mice were incubated for 30 min at 56 ° C to remove nonspecific serum inhibitors.…”

Section: Hai Testmentioning

confidence: 99%

HA1-2-fljB Vaccine Induces Immune Responses against Pandemic Swine-Origin H1N1 Influenza Virus in Mice

Kang

Yang²,

Jiao³

et al. 2016

Microb Physiol

View full text Add to dashboard Cite

In 2009, a novel pandemic swine-origin influenza A (H1N1) virus caused a public emergency of international concern. Vaccination is the primary strategy for the control of influenza epidemics. However, the poor immunopotency of many vaccine antigens is a major barrier to the development of effective vaccines against influenza. Flagellin, a Toll-like receptor 5 (TLR5) ligand, has been used as an adjuvant to enhance the immunopotency of vaccines in preclinical studies. Here, we developed a recombinant candidate vaccine, HA1-2-fljB, in which the globular head of the hemagglutinin (HA) antigen (residues 62-284) from H1N1 virus was fused genetically to the N-terminus of Salmonella typhimurium ﬂjB. The recombinant HA1-2-fljB protein was expressed efficiently in Escherichia coli, and the immunogenicity and protective efficacy of recombinant HA1-2-fljB were evaluated in a mouse model. Immunization with HA1-2-fljB elicited robust IgG antibodies and neutralizing antibodies and completely protected the mice against infection by swine-origin influenza A/swine/Jangsu/38/2010 (H1N1). These results suggest that HA antigen placed at the N-terminus of flagellin is also an excellent starting point for creating a fusion HA1-2-fljB protein as a candidate vaccine, and the recombinant HA1-2-fljB protein will contribute to the development of a more effective vaccine against swine-origin influenza virus infection.

show abstract

Long-Term Protective Immunity from an Influenza Virus-Like Particle Vaccine Administered with a Microneedle Patch

Cited by 58 publications

References 44 publications

Yeast Surface-Displayed H5N1 Avian Influenza Vaccines

Yeast Surface-Displayed H5N1 Avian Influenza Vaccines

Skin permeabilization for transdermal drug delivery: recent advances and future prospects

HA1-2-fljB Vaccine Induces Immune Responses against Pandemic Swine-Origin H1N1 Influenza Virus in Mice

Contact Info

Product

Resources

About